ArticleRetrovirology2025
Drug resistance and genetic transmission characteristics of HIV-1 CRF55_01B in people living with HIV/AIDS (PLWHA) in Henan Province, China.
Article in Retrovirology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmong the many CRFs, CRF55_01B was the first CRF01_AE and subtype B recombinant strain identified around 2013 among men who have sex with men (MSM) in Shenzhen, China. With rapid spreading throughout the country, CRF55_01B has attracted much attention in recent years. This study aimed to analyze its prevalence of drug resistance and transmission characteristics in people living with HIV/AIDS (PLWHA) in Henan province, China so as to pay particular attention to this group of individuals to reduce the incidence of drug resistance.
resultsTwo hundred and forty-five CRF55_01B-infected individuals, including 141 treatment-naïve and 104 treatment-experienced individuals, were enrolled. In treatment-naïve individuals, 6.38% (9/141) of them harboured NRTI DRMs and 19.15% (27/141) of them harboured NNRTI DRMs except V179E/D. In treatment-experienced individuals, 2.00% (2/100) harboured INSTI DRMs, 82.69% (86/104) of them harboured NRTI DRMs, and 88.46% (92/104) of them harboured NNRTI DRMs except V179E/D. The overall prevalence of ADR was 89.42% (93/104), while the prevalence of PDR was 19.86% (28/141). A total of 23 transmission clusters, accounting for 37.55% (92/245) of the total sequences, were identified. The clusters ranged in size from 2 to 19, and 15 (65.22%) had 3 or more sequences.
conclusionsHigh prevalence of DRMs and drug resistance were observed in CRF55_01B in both treatment-naïve and treatment-experienced individuals, particular attention should be paid to this group of individuals to reduce the incidence of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.